These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28208168)

  • 21. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
    Malyukova A; Lahnalampi M; Falqués-Costa T; Pölönen P; Sipola M; Mehtonen J; Teppo S; Akopyan K; Viiliainen J; Lohi O; Hagström-Andersson AK; Heinäniemi M; Sangfelt O
    Genome Biol; 2024 May; 25(1):143. PubMed ID: 38822412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.
    de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O
    Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.
    Diab A; Gem H; Swanger J; Kim HY; Smith K; Zou G; Raju S; Kao M; Fitzgibbon M; Loeb KR; Rodriguez CP; Méndez E; Galloway DA; Sidorova JM; Clurman BE
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28287-28296. PubMed ID: 33093209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
    Wang B; Sun L; Yuan Z; Tao Z
    Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
    Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
    Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
    Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
    Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
    Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
    Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
    [No Abstract]   [Full Text] [Related]  

  • 30. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
    Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K
    Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
    Hashimoto O; Shinkawa M; Torimura T; Nakamura T; Selvendiran K; Sakamoto M; Koga H; Ueno T; Sata M
    BMC Cancer; 2006 Dec; 6():292. PubMed ID: 17177986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
    Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L
    Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833
    [No Abstract]   [Full Text] [Related]  

  • 35. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Not so WEE: targeting G₂/M to kill mesothelioma cells.
    Dent P
    Cancer Biol Ther; 2014 Apr; 15(4):351-2. PubMed ID: 24496096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
    Méndez E; Rodriguez CP; Kao MC; Raju S; Diab A; Harbison RA; Konnick EQ; Mugundu GM; Santana-Davila R; Martins R; Futran ND; Chow LQM
    Clin Cancer Res; 2018 Jun; 24(12):2740-2748. PubMed ID: 29535125
    [No Abstract]   [Full Text] [Related]  

  • 40. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.
    Chen D; Lin X; Gao J; Shen L; Li Z; Dong B; Zhang C; Zhang X
    Biomed Res Int; 2018; 2018():5813292. PubMed ID: 29977914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.